Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 21, 2026

Germany About to Find Out Whether Its Recovery Is Real

View original at finance.yahoo.com
Germany About to Find Out Whether Its Recovery Is Real Photographer: Ben Kilb/Bloomberg (Bloomberg) -- Data from Germany in the coming days will shed light on whether Europe’s largest economy is on the cusp of a meaningful revival or still being hampered by Donald Trump’s tariffs and its own chronic shortcomings…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Calendar-adjusted annual growth would be 0.8% in 2026, up from 0.3% in 2025

    80% confidence
  • Expecting flat fourth-quarter GDP reading for Canada

    80% confidence
  • Central bank would remain cautious on easing

    80% confidence
  • Musings about pulling US out of USMCA trade deal sound like negotiating tactic

    80% confidence
  • Don't anticipate meaningful near-term economic acceleration in Germany, forecasting growth of 0.2% in Q1 2026 and 0.3% in Q2 2026

    80% confidence
  • Increased public spending on infrastructure and defense expected to provide larger boost in second half of 2026, lifting quarterly GDP growth to 0.4%

    80% confidence
  • Stepped up calls for rate cuts

    80% confidence
  • Cited growth in industry and notable strength in construction for Germany's Q4 2025 GDP advance

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com